COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Join the next COVID-19 Webinar
Join thousands of your peers in WCG’s online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from November 20
Most COVID-19 Physiologic Studies Focused on Immunologic Correlates and Responses
We reported previously that 13% of industry-sponsored COVID-19 studies are observational. While most industry-sponsored research are clinical trials, industry sponsors are also collecting data to look at a number of epidemiologic and physiologic questions. In many cases, that data may help support future investigations using real-world data or may provide insight to help develop future therapies or screening programs and diagnostic tests.
Studies of the physiology of COVID-19 are aimed at better understanding risk factors and the biologic effects of infection to support the development of preventive and therapeutic measures. Researchers are looking at the assessment of immunologic correlates and responses (53%), genome sequencing and genetic factors (24%), the microbiome (12%) and coagulopathy correlates and responses (12%).
COVID-19 Trial Progress Tracker Shows 39 Completed Studies
WCG continues to track the progress of global interventional industry-sponsored COVID-19 trials that have been reported as planned/initiated so far this year, now numbering 487. Of those, 39 have been reported as complete, with five completing in the past five weeks. To date, six studies have reported meeting their primary endpoint, with another five reporting they did not meet their endpoint. Notably, 139 studies are still planned for initiation in 2020, so this data will continue to reflect additional activity.
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
FDA Authorizes Use of Dry Heat for Single-User Reuse of Respirators
Specifically, the agency is allowing certain dry heat systems to be used on authorized FFRs that do not have exhalation valves, do not use a duck-bill design and do not contain antimicrobial or antiviral agents.
Anti-Inflammatory Drug Colchicine Investigated for COVID-19 in UK RECOVERY Trial
The UK’s RECOVERY trial, which is evaluating multiple treatments for COVID-19, will add the inexpensive anti-inflammatory drug colchicine to the list of therapies being tested in hospitalized patients.
Moderna Becomes Second Firm to Seek COVID-19 Vaccine Authorization
Moderna on Monday submitted a request for FDA Emergency Use Authorization (EUA) for its coronavirus vaccine, mRNA-1273, making it just the second company to date that’s taken a candidate far enough to file an application for emergency clearance.
FAA Works With Drugmakers, Carriers as First Large-Scale Air Shipment of a Vaccine Goes Out
The Federal Aviation Administration (FAA) confirmed that the first mass air shipment of Pfizer’s COVID-19 vaccine was carried out on Friday.
Novavax Expects Late-Stage U.S./Mexico COVID-19 Vaccine Trial to Start Within Weeks
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled.
Kantaro Gets FDA Authorization for COVID-19 Antibody Test
Kantaro is currently working with Bio-Techne, a biotechnology product manufacturer, to make up to 10 million tests per month.
Vaccine Nonprofit Covaxx Secures $2.8 Billion Supply Deals
The vaccine can be stored at normal refrigeration temperatures.
Vaccine Consortium Covaxx Inks Supply Deals Worth $2.8 billion
United Biomedical’s nonprofit vaccine subsidiary, Covaxx, said it has secured supply deals worth $2.8 billion for more than 140 million doses of its COVID-19 vaccine candidate, UB-612, in “multiple countries,” including Brazil, Ecuador and Peru.
EU Seeks to Skirt Patent Rights During Crises to Speed Generics
The European Commission (EC) last week adopted an ambitious drug access strategy inspired by the COVID-19 pandemic that proposes allowing generics manufacturers to sidestep having to get patent permissions during public health emergencies.
BioNTech and Fosun Pharma Begin Phase 2 COVID-19 Vaccine Trial in China
German drugmaker BioNTech and China’s Fosun Pharmaceutical Group have announced that the Pfizer/BioNTech COVID-19 vaccine candidate, BNT162b2, will be evaluated in a phase 2 study in China, building on an agreement the companies signed in March.
AstraZeneca Likely to Start New Global COVID-19 Vaccine Trial to Verify Effectiveness
AstraZeneca’s COVID-19 vaccine candidate is facing another potential delay as the company plans to undertake a new global clinical trial to confirm the vaccine’s 90 percent efficacy based on a one-and-a-half-dose regimen.
EMA Hopeful It Can Authorize a COVID-19 Vaccine by Christmas
The new head of the European Medicines Agency (EMA), Emer Cooke, said she is “hopeful” that the agency will grant a conditional marketing authorization for a COVID-19 vaccine by Christmas.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.